{"title":"Side Effect Driven Conversion to Belatacept for Kidney Transplant Recipients in a Clinical Setting","authors":"","doi":"10.33140/jcei.05.01.03","DOIUrl":null,"url":null,"abstract":"Maintenance immunosuppression after kidney transplantation is critical to graft and patient survival. However, the optimal\nimmunosuppressive medication may differ for patients based on adverse effects. Here we report one-year outcomes of 73 kidney\ntransplant patients converted from tacrolimus to belatacept because of adverse effects at least 90 days after transplant.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical & experimental immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/jcei.05.01.03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Maintenance immunosuppression after kidney transplantation is critical to graft and patient survival. However, the optimal
immunosuppressive medication may differ for patients based on adverse effects. Here we report one-year outcomes of 73 kidney
transplant patients converted from tacrolimus to belatacept because of adverse effects at least 90 days after transplant.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
